In their statement, they mention that a new treatment called bulevirtide has been registered in Kyrgyzstan for the treatment of delta hepatitis; however, the diagnosis and therapy for HDV are still carried out under the hepatitis B protocol.
According to ECAT, the lack of separate clinical guidelines and program documents for delta hepatitis diminishes the significance of this disease and limits opportunities for funding and planning assistance for patients.
The letter also presents data from the Republican Center for the Control of Hematogenic Viral Hepatitis and HIV, according to which, as of September 1, 2025, 17% of patients with hepatitis B (3,120 people) suffer from coinfection with delta hepatitis.
Thus, ECAT representatives request the Ministry of Health to consider two main proposals:
- the creation of a working group involving patients to develop and implement a national program for delta hepatitis with a separate budget,
- the development and approval of clinical guidelines for HDV as a separate nosology.
The image on the main page is for illustrative purposes: gemotest.ru.
